- Home
- GSL vs COLL Comparison
GSL vs COLL Comparison
Compare GSL & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- COLL
- Stock Information
- Founded
- GSL 2007
- COLL 2002
- Country
- GSL Greece
- COLL United States
- Employees
- GSL N/A
- COLL N/A
- Industry
- GSL Marine Transportation
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- COLL Health Care
- Exchange
- GSL Nasdaq
- COLL Nasdaq
- Market Cap
- GSL 1.1B
- COLL 958.8M
- IPO Year
- GSL 2006
- COLL 2015
- Fundamental
- Price
- GSL $31.92
- COLL $37.32
- Analyst Decision
- GSL Strong Buy
- COLL Strong Buy
- Analyst Count
- GSL 1
- COLL 4
- Target Price
- GSL $33.00
- COLL $44.25
- AVG Volume (30 Days)
- GSL 317.1K
- COLL 433.7K
- Earning Date
- GSL 11-10-2025
- COLL 11-06-2025
- Dividend Yield
- GSL 6.58%
- COLL N/A
- EPS Growth
- GSL 19.05
- COLL N/A
- EPS
- GSL 10.76
- COLL 1.06
- Revenue
- GSL $730,277,000.00
- COLL $707,007,000.00
- Revenue This Year
- GSL $5.44
- COLL $22.23
- Revenue Next Year
- GSL N/A
- COLL $2.78
- P/E Ratio
- GSL $2.97
- COLL $35.25
- Revenue Growth
- GSL 4.04
- COLL 22.61
- 52 Week Low
- GSL $17.73
- COLL $23.23
- 52 Week High
- GSL $32.45
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- GSL 69.71
- COLL 50.80
- Support Level
- GSL $31.00
- COLL $37.10
- Resistance Level
- GSL $31.78
- COLL $39.12
- Average True Range (ATR)
- GSL 0.51
- COLL 1.09
- MACD
- GSL 0.09
- COLL -0.38
- Stochastic Oscillator
- GSL 83.28
- COLL 8.55
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.